Skip to main content

Table 5 Change in clinical and functional status between baseline and one year by APR levels

From: Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

 

Neither APR elevated

APR levels discordant

Both APR elevated

P value

 

n = 2,520

n = 1,058

n = 650

 

mHAQ

0.01 ± 0.31

-0.03 ± 0.40

-0.10 ± 0.43

<0.0001

CDAI

-2.40 ± 10.87

-3.92 ± 12.37

-7.68 ± 14.19

<0.0001

Tender joints

-0.69 ± 5.48

-1.28 ± 5.81

-2.75 ± 6.98

<0.0001

Swollen joints

-1.12 ± 5.11

-1.49 ± 5.53

-2.58 ± 5.95

<0.0001

Patient global assessment

-2.38 ± 25.21

-4.90 ± 27.78

-11.29 ± 30.11

<0.0001

MD global assessment

-4.21 ± 17.30

-6.45 ± 19.78

-12.57 ± 23.19

<0.0001

  1. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.